Literature DB >> 10065772

The role of luteinizing hormone in folliculogenesis and ovulation induction.

M Filicori1.   

Abstract

OBJECTIVE: To review the physiologic, pathophysiologic, and clinical roles of LH in follicle and oocyte development and maturation and to assess the effects of LH content in exogenous gonadotropin preparations used for ovulation induction.
DESIGN: Critical review of the scientific literature devoted to folliculogenesis. Evaluation of comparison studies that used different gonadotropin preparations for ovulation induction. CONCLUSION(S): Folliculogenesis and oocyte maturation are complex processes that require the action of both LH and FSH. Luteinizing hormone is essential to provide the androgen substrate for estrogen synthesis, which in turn contributes to oocyte maturation and may play a relevant role in optimizing fertilization and embryo quality. Although the excessive LH secretion that is present in some disorders is detrimental to reproductive function, this is not applicable to ovulation induction with hMG because this menotropin does not increase daily plasma LH levels. The results of ovulation induction with hMG or FSH-only regimens did not differ in studies conducted in patients with polycystic ovary syndrome and in most studies conducted in ovulatory women undergoing assisted reproductive techniques; conversely, hMG was clearly superior to purified FSH for the treatment of hypogonadotropic hypogonadism. Miscarriage rates were not affected by the use of hMG. Thus, low but detectable LH concentrations positively influence the outcome of ovulation induction in patients with ovulatory disorders and women undergoing assisted reproductive techniques.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065772     DOI: 10.1016/s0015-0282(98)00482-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  22 in total

Review 1.  The normal human menstrual cycle.

Authors:  N Chabbert-Buffet; P Bouchard
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer.

Authors:  Ming-Ting Chung; Yung-Chieh Tsai; Sheng-Hsien Chen; Tao-Chuan Loo; Hsun-Han Tang; Liang-Yin Lin
Journal:  J Assist Reprod Genet       Date:  2006-08-16       Impact factor: 3.412

3.  LH (Trp8Arg/Ile15Thr), LHR (insLQ) and FSHR (Asn680Ser) polymorphisms genotypic prevalence in women with endometriosis and infertility.

Authors:  Carla Regina Schmitz; Carlos Augusto Bastos de Souza; Vanessa Krebs Genro; Ursula Matte; Emily de Conto; João Sabino Cunha-Filho
Journal:  J Assist Reprod Genet       Date:  2015-05-03       Impact factor: 3.412

Review 4.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

5.  Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study.

Authors:  Rafal Kurzawa; Przemyslaw Ciepiela; Tomasz Baczkowski; Krzysztof Safranow; Pawel Brelik
Journal:  J Assist Reprod Genet       Date:  2008-09-19       Impact factor: 3.412

6.  The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.

Authors:  J Balasch; M Creus; F Fábregues; S Civico; F Carmona; B Puerto; R Casamitjana; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2001-05       Impact factor: 3.412

7.  Inhibitory role of prohibitin in human ovarian epithelial cancer.

Authors:  Lin Jia; Jian-Min Ren; Yi-Ying Wang; Yu Zheng; Hui Zhang; Qing Zhang; Bei-Hua Kong; Wen-Xin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.

Authors:  Su-Long Lee; Jinu-Hwang Su; Katsuo Ikuta; Kaoru Suzumori
Journal:  Reprod Med Biol       Date:  2003-03-25

9.  Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.

Authors:  Shao-Hua Xie; Rui Fang; Mingtao Huang; Juncheng Dai; Aaron P Thrift; Lesley A Anderson; Wong-Ho Chow; Leslie Bernstein; Marilie D Gammon; Harvey A Risch; Nicholas J Shaheen; Brian J Reid; Anna H Wu; Prasad G Iyer; Geoffrey Liu; Douglas A Corley; David C Whiteman; Carlos Caldas; Paul D Pharoah; Laura J Hardie; Rebecca C Fitzgerald; Hongbing Shen; Thomas L Vaughan; Jesper Lagergren
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-19       Impact factor: 11.382

10.  Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Alessandro Conforti; Sandro C Esteves; Peter Humaidan; Salvatore Longobardi; Thomas D'Hooghe; Raoul Orvieto; Alberto Vaiarelli; Danilo Cimadomo; Laura Rienzi; Filippo Maria Ubaldi; Fulvio Zullo; Carlo Alviggi
Journal:  Reprod Biol Endocrinol       Date:  2021-06-21       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.